Literature DB >> 35355698

The CHEK2*1100delC Mutation and Adolescent Breast Cancer: A Case Report of Breast Cancer in a 19-Year-Old and a Review of the Literature.

Tahereh Soleimani1, Abigail J Engwall1, Corrie Bourdon2, Mohammad A Torabi1, Thais Fortes2.   

Abstract

Background: Breast cancer (BC) is the most common non-skin cancer affecting women but is extremely uncommon in the adolescent population. Genetic inheritance has been linked to <10% of BCs. CHEK2 is an uncommon genetic variant with a reported incidence of 0.3-1.6% in the general population and 4.9-5.7% in those with a family history of BC. Commonly, this mutation presents in females of European descent and is rare in North America. Case Presentation: A 19-year-old Caucasian female presented with breast pain and mass. She had an extensive family history of cancer, as well as a known CHEK2 gene mutation in 2 of her paternal aunts. Ultrasound and MRI confirmed a 4.5-cm mass with an enlarged right axillary lymph node. Image guided biopsy of the breast mass showed ER/PR-positive grade 1 invasive mucinous ductal cancer. Genetic testing confirmed an isolated CHEK2 mutation. After discussion by a multidisciplinary tumor board, the patient deferred bilateral mastectomy and underwent a right mastectomy with sentinel-lymph-node biopsy and immediate tissue-expander reconstruction. Final pathology confirmed ER/PR-positive Stage 1A (pT2 pN0 M0) invasive mucinous carcinoma. Chemotherapy was not recommended. Summary: Malignant adolescent breast masses are relatively rare and CHEK2 does not typically present at younger than 20 years of age. While there are many different differential diagnoses when evaluating an adolescent with a breast mass, we wish to increase providers' suspicion of malignancy, specifically in those individuals who have a strong family history of BC and the CHEK2*1100delC mutation.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Adolescent; Breast cancer; CHEK2; Checkpoint kinase 2; Family history; Genetic variant

Year:  2021        PMID: 35355698      PMCID: PMC8914274          DOI: 10.1159/000513679

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  21 in total

1.  Absence of CHEK2 mutations in Spanish families with hereditary breast cancer.

Authors:  Beatriz Bellosillo; Ignacio Tusquets; Raquel Longarón; Anna Pérez-Lezaun; Meritxell Bellet; Xavier Fabregat; Sergi Serrano; Francesc Solé
Journal:  Cancer Genet Cytogenet       Date:  2005-08

2.  Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America.

Authors:  Maria D Iniesta; Michael A Gorin; Ling-Chen Chien; Samantha M Thomas; Kara J Milliron; Julie A Douglas; Sofia D Merajver
Journal:  Cancer Genet Cytogenet       Date:  2010-10-15

3.  CHEK2 1100delC variant and breast cancer risk in Caucasians: a meta-analysis based on 25 studies with 29,154 cases and 37,064 controls.

Authors:  Yuan Yang; Fan Zhang; Yang Wang; Sheng-Chun Liu
Journal:  Asian Pac J Cancer Prev       Date:  2012

4.  Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.

Authors:  D W Bell; J M Varley; T E Szydlo; D H Kang; D C Wahrer; K E Shannon; M Lubratovich; S J Verselis; K J Isselbacher; J F Fraumeni; J M Birch; F P Li; J E Garber; D A Haber
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

Review 5.  Breast cancer in adolescents and young adults.

Authors:  Rebecca H Johnson; Carey K Anders; Jennifer K Litton; Kathryn J Ruddy; Archie Bleyer
Journal:  Pediatr Blood Cancer       Date:  2018-08-28       Impact factor: 3.167

6.  Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.

Authors:  Cezary Cybulski; Dominika Wokołorczyk; Anna Jakubowska; Tomasz Huzarski; Tomasz Byrski; Jacek Gronwald; Bartłomiej Masojć; Tadeusz Deebniak; Bohdan Górski; Paweł Blecharz; Steven A Narod; Jan Lubiński
Journal:  J Clin Oncol       Date:  2011-08-29       Impact factor: 44.544

7.  Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study.

Authors:  Shiyu Zhang; Catherine M Phelan; Phil Zhang; Francois Rousseau; Parviz Ghadirian; Andre Robidoux; William Foulkes; Nancy Hamel; David McCready; Maureen Trudeau; Henry Lynch; Douglas Horsman; Maria Lourdes Leon De Matsuda; Zeba Aziz; Magda Gomes; Mauricio Magalhaes Costa; Alexander Liede; Aletta Poll; Ping Sun; Steven A Narod
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

8.  A Comparison between CHEK2*1100delC/I157T Mutation Carrier and Noncarrier Breast Cancer Patients: A Clinicopathological Analysis.

Authors:  Joanna Huszno; Magdalena Budryk; Zofia Kołosza; Karolina Tęcza; Jolanta Pamuła Piłat; Elżbieta Nowara; Ewa Grzybowska
Journal:  Oncology       Date:  2016-03-19       Impact factor: 2.935

9.  Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individuals.

Authors:  C R Jekimovs; X Chen; J Arnold; M Gatei; D J Richard; A B Spurdle; K K Khanna; G Chenevix-Trench
Journal:  Br J Cancer       Date:  2005-02-28       Impact factor: 7.640

10.  Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy.

Authors:  M Kriege; A Hollestelle; A Jager; P E A Huijts; E M Berns; A M Sieuwerts; M E Meijer-van Gelder; J M Collée; P Devilee; M J Hooning; J W M Martens; C Seynaeve
Journal:  Br J Cancer       Date:  2014-06-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.